Provided by Tiger Trade Technology Pte. Ltd.

Sanofi SA

45.64
-0.2057-0.45%
Volume:1.05M
Turnover:47.78M
Market Cap:109.36B
PE:24.48
High:45.70
Open:45.49
Low:45.32
Close:45.85
52wk High:52.68
52wk Low:40.89
Shares:2.40B
Float Shares:2.16B
Volume Ratio:0.65
T/O Rate:0.05%
Dividend:2.40
Dividend Rate:5.26%
EPS(TTM):1.86
EPS(LYR):3.76
ROE:5.71%
ROA:5.09%
PB:1.36
PE(LYR):12.14

Loading ...

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live
·
Jun 17

European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading

MT Newswires Live
·
Jun 15

Sanofi Says US FDA Approved Tzield for Recently Diagnosed Stage 3 Type 1 Diabetes in Children

MT Newswires Live
·
Jun 15

Sanofi's Tzield Receives FDA Approval for Diabetes Treatment

Dow Jones
·
Jun 13

Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright

TIPRANKS
·
Jun 10

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Renewed US-Iran Clashes

MT Newswires Live
·
Jun 10

Dianthus sinks after Sanofi halts CIDP Phase 3 study

TIPRANKS
·
Jun 10

Sanofi to halt riliprubart Mobilize phase 3 study

TIPRANKS
·
Jun 10

Sanofi's Development Pipeline Stumbles Again as Rare Disease Drug Trial Halts, Adding Pressure on New CEO

Stock News
·
Jun 10

Sanofi Stops Late-Stage Trial of Autoimmune Disease Therapy After Interim Review

MT Newswires Live
·
Jun 10

Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

Dow Jones
·
Jun 10

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires Live
·
Jun 08

Sanofi's Subcutaneous Sarclisa Approved in EU Across Multiple Myeloma Indications

MT Newswires Live
·
Jun 08

Movement Alert|Sanofi Rises 4.59% in Regular Trading, First-in-Class Drug Venglustat Granted FDA Priority Review for Rare Disease

Market Focus
·
Jun 04

Movement Alert|Sanofi Rises 3.09% in Pre-Market Trading, First-in-Class Drug Venglustat Granted FDA Priority Review

Market Focus
·
Jun 04

Sanofi's Groundbreaking Drug Venglustat Seeks FDA Approval for Type 3 Gaucher Disease

Stock News
·
May 28

Sanofi announces FDA grants priority review to venglustat new drug application

TIPRANKS
·
May 28

Sanofi Granted FDA Priority Review for Potential Treatment of Rare Gaucher Disease

MT Newswires Live
·
May 28

Sanofi reports ElevAATe trial of efdoralprin alfa meets primary endpoint

TIPRANKS
·
May 19

Regeneron Pharmaceuticals Trial Miss May Raise Broader Strategy Questions, RBC Says

MT Newswires Live
·
May 18